All Indian children aged 12 or older will become eligible for Covid-19 vaccinations from next month, when drug maker Cadila Healthcare launches its ZyCoV-D product, two sources with direct knowledge of the matter told Reuters.
The world's first DNA-based Covid-19 vaccine, ZyCoV-D won emergency authorisation from Indian regulators last month. From October, the company, better known as Zydus Cadila, will produce 10 million doses a month.
The health ministry did not immediately respond to a request for comment. The sources sought anonymity because they were not authorised to talk to media.
The vaccine is the only one approved for children in India, which has given a total of 825.9 million doses to adults among its population of nearly 1.4 billion.
(Reporting by Neha Arora and Krishna N. Das; Editing by Clarence Fernandez)
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.